Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a two-phase, multicenter, open phase I clinical study, with phase Ia as dose
escalation phase and phase Ib as dose expansion phase, to evaluate the safety tolerability
and pharmacokinetic characteristics of BEBT-607 tablets in patients with advanced or
metastatic solid tumors associated with KRAS G12C mutation. To evaluate the efficacy of
BEBT-607 tablets in the treatment of patients with advanced or metastatic solid tumors with
KRAS G12C mutation, and to determine the recommended dose (RP2D) for Phase II clinical trials
of BEBT-607 tablets in patients with advanced or metastatic solid tumors with KRAS G12C
mutation.